Imperial College London

Dr Gaia Kiru

Faculty of MedicineSchool of Public Health

Head of Operations & Partnerships - ICTU Commercial
 
 
 
//

Contact

 

g.kiru

 
 
//

Location

 

Stadium HouseWhite City Campus

//

Summary

 

Summary

Dr Gaia Kiru joined Imperial College in 2007 and currently holds the position of Head of Operations & Partnerships within the UKCRC registered Imperial Clinical Trials Unit (ICTU) in the School of Public Health within the Faculty of Medicine at Imperial College.

Gaia has over 15 years experience of managing both academic and commercial clinical trials and studies, both in the UK and internationally - including protocol design, ethics and regulatory submissions, budget control, pharmacovigilance, monitoring, data management, drug supply and recruitment and retention of trial subjects. 

Although her background and expertise lies mainly in the cardiovascular field, she has worked in several therapeutic areas including oncology, respiratory, orthopaedics, haematology and vaccines. 

Qualifications

PhD - Imperial College London. Thesis titled: Investigating the roles of central and peripheral blood pressure and blood pressure variability on the size and growth of Abdominal Aortic Aneurysms. 

MBA Health Services Management - University of Plymouth 

MSc Pharmacology - Kings College London

BSc Human Biology - Kings College London

Publications

Journals

Ray K, Molemans B, Schoonen WM, et al., 2020, EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study, European Journal of Preventive Cardiology, ISSN:2047-4873

Bicknell CD, Kiru G, Falaschetti E, et al., 2016, An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: A randomised placebo controlled trial (AARDVARK), European Heart Journal, Vol:37, ISSN:1522-9645, Pages:3213-3221

Kiru G, Bicknell C, Falaschetti E, et al., 2016, An evaluation of the effect of an angiotensin-converting enzyme inhibitor on the growth rate of small abdominal aortic aneurysms: a randomised placebo-controlled trial (AARDVARK), Health Technology Assessment, Vol:20, ISSN:1366-5278

Lewis SM, Treacher DF, Edgeworth J, et al., 2015, Expression of CD11c and EMR2 on neutrophils: potential diagnostic biomarkers for sepsis and systemic inflammation, Clinical & Experimental Immunology, Vol:182, ISSN:0009-9104, Pages:184-194

Cabrita IZ, Mohammed A, Layton M, et al., 2013, The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom, British Journal of Haematology, Vol:162, ISSN:0007-1048, Pages:400-408

More Publications